<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39559920</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2190-6009</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of cachexia, sarcopenia and muscle</Title><ISOAbbreviation>J Cachexia Sarcopenia Muscle</ISOAbbreviation></Journal><ArticleTitle>Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcsm.13628</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Long COVID-19 illness is a severely disabling disease with shortness of breath, weakness and fatigue as leading symptoms, resulting in poor quality of life and substantial delay in return to work. No specific respiratory therapy has been validated for patients with long COVID. The intermittent hypoxia-hyperoxia training (IHHT) is a respiratory therapeutic modality to improve exercise performance via controlled respiratory conditioning. The purpose of the present study is to investigate the therapeutic effect of IHHT on functional and symptomatic recovery of patients with long COVID syndrome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, controlled, open-treatment interventional study was conducted in patients with long COVID who were admitted to an inpatient rehabilitation programme. Patients were assigned nonrandomized to receive IHHT in addition to the standardized rehabilitation programme (IHHT group) or standard rehabilitation alone (control group). The IHHT group received supervised sessions of intermittent hypoxic (10-12% O<sub>2</sub>) and hyperoxic (30-35% O<sub>2</sub>) breathing three times per week throughout the rehabilitation period. Primary endpoint was improved walking distance in a 6-min walk test (6MWT) between study groups. Secondary endpoints were change in stair climbing power, dyspnoea (Borg dyspnoea Scale), fatigue assessment scale (FAS) and change in health-related quality of life (HRQoL) assessed by patient global assessment (PGA), EQ-5D analogue scale and the MEDIAN Corona Recovery Score (MCRS). Further assessments included maximum handgrip strength, nine hole peg test, timed up-and-go, respiratory function and functional ambulation category (FAC), serum analyses and safety of the intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 145 patients were included in the study (74% female, mean age 53&#x2009;&#xb1;&#x2009;12 years) and assigned to IHHT (n&#x2009;=&#x2009;70) or standard care (n&#x2009;=&#x2009;75). The 6MWT distance improved 2.8-fold in the IHHT group compared to the control group (91.7&#x2009;&#xb1;&#x2009;50.1&#x2009;m vs. 32.6&#x2009;&#xb1;&#x2009;54.2&#x2009;m, ANCOVA p&#x2009;&lt;&#x2009;0.001). Stair climbing power improved 3.7-fold in the IHHT group compared to controls (-1.91&#x2009;&#xb1;&#x2009;2.23&#x2009;s vs. -0.51&#x2009;&#xb1;&#x2009;1.93&#x2009;s, p&#x2009;&lt;&#x2009;0.001). Secondary endpoints on dyspnoea, fatigue and HRQoL (PGA, EQ-5D and MCRS) improved significantly in the IHHT group compared to controls. The IHHT group exhibited a significant decrease in blood pressure, heart rate and increase in haemoglobin levels that was not observed in the control group. No adverse events were observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Respiratory treatment with IHHT in addition to a multidisciplinary rehabilitation programme improves functional capacity, symptomatic status and quality of life in patients with disabling long COVID. IHHT has been demonstrated to be safe, well tolerated and feasible to be integrated in an inpatient rehabilitation programme to improve outcome in long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doehner</LastName><ForeName>Wolfram</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-7598-708X</Identifier><AffiliationInfo><Affiliation>Berlin Institute of Health Center for Regenerative Therapies, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Heart Center of the Charite, Department of Cardiology, Campus Virchow, German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Stroke Research Berlin (CSB), Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Berlin Institute of Health Center for Regenerative Therapies, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alimi</LastName><ForeName>Banafsheh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie und Pneumologie, Median Klinikum Flechtingen, Flechtingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhar</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie und Pneumologie, Median Klinikum Flechtingen, Flechtingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Springer</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Berlin Institute of Health Center for Regenerative Therapies, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MVZ Cardiologicum Dresden und Pirna, Studienzentrum Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schueller</LastName><ForeName>Per Otto</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Kardiologie und Pneumologie, Median Klinikum Flechtingen, Flechtingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Cachexia Sarcopenia Muscle</MedlineTA><NlmUniqueID>101552883</NlmUniqueID><ISSNLinking>2190-5991</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6&#x2009;min walking test</Keyword><Keyword MajorTopicYN="N">hypoxia</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">rehabilitation</Keyword><Keyword MajorTopicYN="N">training</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39559920</ArticleId><ArticleId IdType="doi">10.1002/jcsm.13628</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Lopez&#x2010;Leon, T. Wegman&#x2010;Ostrosky, C. Perelman, et&#xa0;al., &#x201c;More Than 50 Long&#x2010;Term Effects of COVID&#x2010;19: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Scientific Reports 11 (2021): 16144.</Citation></Reference><Reference><Citation>NICE, &#x201c;Guideline on Management of Long COVID,&#x201d; https://www.nice.org.uk/guidance/NG188.</Citation></Reference><Reference><Citation>A. DeVries, S. Shambhu, S. Sloop, and J. M. Overhage, &#x201c;One&#x2010;Year Adverse Outcomes Among US Adults With Post&#x2010;COVID&#x2010;19 Condition vs Those Without COVID&#x2010;19 in a Large Commercial Insurance Database,&#x201d; JAMA Health Forum 4 (2023): e230010, https://doi.org/10.1001/jamahealthforum.2023.0010.</Citation></Reference><Reference><Citation>R. S. Peter, A. Nieters, H. G. Kr&#xe4;usslich, et&#xa0;al., &#x201c;EPILOC Phase 1 Study Group. Post&#x2010;Acute Sequelae of Covid&#x2010;19 six to 12 Months After Infection: Population Based Study,&#x201d; BMJ 379 (2022): e071050, https://doi.org/10.1136/bmj&#x2010;2022&#x2010;071050.</Citation></Reference><Reference><Citation>M. Rahmati, R. Udeh, D. K. Yon, et&#xa0;al., &#x201c;A Systematic Review and Meta&#x2010;Analysis of Long&#x2010;Term Sequelae of COVID&#x2010;19 2&#x2010;Year After SARS&#x2010;CoV&#x2010;2 Infection: A Call to Action for Neurological, Physical, and Psychological Sciences,&#x201d; Journal of Medical Virology 95 (2023): e28852, https://doi.org/10.1002/jmv.28852.</Citation></Reference><Reference><Citation>Y. Shi, R. Strobl, C. Apfelbacher, et&#xa0;al., &#x201c;Persistent Symptoms and Risk Factors Predicting Prolonged Time to Symptom&#x2010;Free After SARS&#x2010;CoV&#x2010;2 Infection: An Analysis of the Baseline Examination of the German COVIDOM/NAPKON&#x2010;POP Cohort,&#x201d; Infection 51 (2023): 1679&#x2013;1694.</Citation></Reference><Reference><Citation>L. L. O'Mahoney, A. Routen, C. Gillies, et&#xa0;al., &#x201c;The Prevalence and Long&#x2010;Term Health Effects of Long Covid Among Hospitalised and Non&#x2010;Hospitalised Populations: A Systematic Review and Meta&#x2010;Analysis,&#x201d; EClinicalMedicine 55 (2022): 101762.</Citation></Reference><Reference><Citation>L. D. Hayes, J. Ingram, and N. F. Sculthorpe, &#x201c;More Than 100 Persistent Symptoms of SARS&#x2010;CoV&#x2010;2 (Long COVID): A Scoping Review,&#x201d; Frontiers in Medicine 8 (2021): 750378.</Citation></Reference><Reference><Citation>E. Flouda, A. Stefanatou, and T. Apergi, &#x201c;Intervention Options: Depression and Cardiovascular Disease During COVID19,&#x201d; Global Cardiology 1 (2023): 13&#x2013;21.</Citation></Reference><Reference><Citation>D. Liska, E. Liptakova, A. Babicova, et&#xa0;al., &#x201c;What Is the Quality of Life in Patients With Long COVID Compared to a Healthy Control Group?,&#x201d; Frontiers in Public Health 10 (2022): 975992, https://doi.org/10.3389/fpubh.2022.975992.</Citation></Reference><Reference><Citation>Techniker Krankenkasse Gesundheitsreport, &#x201c;zum Schwerpunkt LONG&#x2010;COVID,&#x201d; (2022), https://www.tk.de/resource/blob/2129682/70045874c0f603398581fe24de20219f/tk&#x2010;gesundheitsreport&#x2010;2022&#x2010;schwerpunkt&#x2010;long&#x2010;covid&#x2010;data.pdf.</Citation></Reference><Reference><Citation>B. Raman, M. P. Cassar, E. M. Tunnicliffe, et&#xa0;al., &#x201c;Medium&#x2010;Term Effects of SARS&#x2010;CoV&#x2010;2 Infection on Multiple Vital Organs, Exercise Capacity, Cognition, Quality of Life and Mental Health, Post&#x2010;Hospital Discharge,&#x201d; EClinicalMedicine 31 (2021): 100683, https://doi.org/10.1016/j.eclinm.2020.100683.</Citation></Reference><Reference><Citation>S. Su, Y. Zhao, N. Zeng, et&#xa0;al., &#x201c;Epidemiology, Clinical Presentation, Pathophysiology, and Management of Long COVID: An Update,&#x201d; Molecular Psychiatry 28 (2023): 4056&#x2013;4069.</Citation></Reference><Reference><Citation>R. Torres&#x2010;Castro, L. Vasconcello&#x2010;Castillo, X. Alsina&#x2010;Restoy, et&#xa0;al., &#x201c;Respiratory Function in Patients Post&#x2010;Infection by COVID&#x2010;19: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Pulmonology 27 (2021): 328&#x2013;337.</Citation></Reference><Reference><Citation>M. A. Spruit, A. E. Holland, S. J. Singh, et&#xa0;al., &#x201c;COVID&#x2010;19: Interim Guidance on Rehabilitation in the Hospital and Post&#x2010;Hospital Phase From a European Respiratory Society and American Thoracic Society&#x2010;Coordinated International Task Force,&#x201d; European Respiratory Journal 56 (2020): 2002197, https://doi.org/10.1183/13993003.02197&#x2010;2020.</Citation></Reference><Reference><Citation>R. Glockl, H. Buhr&#x2010;Schinner, and A. R. Koczulla, &#x201c;Recommendations From the German Respiratory Society for Pulmonary Rehabilitation in Patients With COVID&#x2010;19,&#x201d; Pneumologie 74 (2020): 496&#x2013;504.</Citation></Reference><Reference><Citation>A. Westmacott, N. E. M. Sanal&#x2010;Hayes, M. McLaughlin, J. L. Mair, and L. D. Hayes, &#x201c;High&#x2010;Intensity Interval Training (HIIT) in Hypoxia Improves Maximal Aerobic Capacity More Than HIIT in Normoxia: A Systematic Review, Meta&#x2010;Analysis, and Meta&#x2010;Regression,&#x201d; International Journal of Environmental Research and Public Health 19 (2022): 14261, https://doi.org/10.3390/ijerph192114261.</Citation></Reference><Reference><Citation>O. Saeed, V. Bhatia, P. Formica, et&#xa0;al., &#x201c;Improved Exercise Performance and Skeletal Muscle Strength After Simulated Altitude Exposure: A Novel Approach for Patients With Chronic Heart Failure,&#x201d; Journal of Cardiac Failure 18 (2012): 387&#x2013;391.</Citation></Reference><Reference><Citation>E. Dudnik, E. Zagaynaya, O. S. Glazachev, and D. Susta, &#x201c;Intermittent Hypoxia&#x2010;Hyperoxia Conditioning Improves Cardiorespiratory Fitness in Older Comorbid Cardiac Outpatients Without Hematological Changes: A Randomized Controlled Trial,&#x201d; High Altitude Medicine &amp; Biology 19 (2018): 339&#x2013;343.</Citation></Reference><Reference><Citation>T. Behrendt, R. Bielitzki, M. Behrens, O. S. Glazachev, and L. Schega, &#x201c;Effects of Intermittent Hypoxia&#x2010;Hyperoxia Exposure Prior to Aerobic Cycling Exercise on Physical an Cognitive Performance in Geriatric Patients&#x2014;A Randomized Controlled Trial,&#x201d; Frontiers in Physiology 13 (2022): 899096, https://doi.org/10.3389/fphys.2022.899096.</Citation></Reference><Reference><Citation>U. Bayer, R. Likar, G. Pinter, et&#xa0;al., &#x201c;Intermittent Hypoxic&#x2010;Hyperoxic Training on Cognitive Performance in Geriatric Patients,&#x201d; Alzheimers Dement (NY) 3 (2017): 114&#x2013;122.</Citation></Reference><Reference><Citation>O. S. Glazachev, E. N. Dudnik, M. A. Zapara, V. G. Samarceva, and W. W. Kofler, &#x201c;Adaptation to Dosed Hypoxia&#x2010;Hyperoxia as Factor in Improving the Quality of Life of Patients With Cardiac Pathology,&#x201d; Advances in Gerontology 32 (2019): 145&#x2013;151.</Citation></Reference><Reference><Citation>O. Glazachev, P. Kopylov, D. Susta, E. Dudnik, and E. Zagaynaya, &#x201c;Adaptation Following an Intermittent Hypoxia&#x2010;Hyperoxia Training in Coronary Artery Disease Patients: A Controlled Study,&#x201d; Clinical Cardiology 40 (2017): 370&#x2013;376.</Citation></Reference><Reference><Citation>O. S. Glazachev, S. Y. Kryzhanovskaya, M. A. Zapara, E. N. Dudnik, V. G. Samartseva, and D. Susta, &#x201c;Safety and Efficacy of Intermittent Hypoxia Conditioning as a New Rehabilitation/Secondary Prevention Strategy for Patients With Cardiovascular Diseases: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Current Cardiology Reviews 17 (2021): e051121193317.</Citation></Reference><Reference><Citation>Ergebnisqualitaet bei Long COVID, &#x201c;MEDIAN Qualitaetsbericht, 2021&#x2013;2022a. Chapter&#xa0;4.7,&#x201d; 146&#x2013;149, accessed 22 February 2024, https://www.median&#x2010;kliniken.de/fileadmin/qualitatsbericht/index.html.</Citation></Reference><Reference><Citation>T. T&#xe4;ger, W. Hanholz, R. Cebola, et&#xa0;al., &#x201c;Minimal Important Difference for 6&#x2010;Minute Walk Test Distances Among Patients With Chronic Heart Failure,&#x201d; International Journal of Cardiology 176 (2014): 94&#x2013;98.</Citation></Reference><Reference><Citation>N. Muangritdech, M. J. Hamlin, K. Sawanyawisuth, et&#xa0;al., &#x201c;Hypoxic Training Improves Blood Pressure, Nitric Oxide and Hypoxia&#x2010;Inducible Factor&#x2010;1 Alpha in Hypertensive Patients,&#x201d; European Journal of Applied Physiology 120 (2020): 1815&#x2013;1826.</Citation></Reference><Reference><Citation>T. V. Serebrovska, A. G. Portnychenko, T. I. Drevytska, et&#xa0;al., &#x201c;Intermittent Hypoxia Training in Prediabetes Patients: Beneficial Effects on Glucose Homeostasis, Hypoxia Tolerance and Gene Expression,&#x201d; Experimental Biology and Medicine (Maywood, N.J.) 242 (2017): 1542&#x2013;1552.</Citation></Reference><Reference><Citation>P. Ponikowski, D. J. van Veldhuisen, J. Comin&#x2010;Colet, et&#xa0;al., &#x201c;Beneficial Effects of Long&#x2010;Term Intravenous Iron Therapy With Ferric Carboxymaltose in Patients With Symptomatic Heart Failure and Iron Deficiency,&#x201d; European Heart Journal 36 (2015): 657&#x2013;668.</Citation></Reference><Reference><Citation>S. D. Anker, J. Comin Colet, G. Filippatos, et&#xa0;al., &#x201c;Ferric Carboxymaltose in Patients With Heart Failure and Iron Deficiency,&#x201d; New England Journal of Medicine 361 (2009): 2436&#x2013;2448.</Citation></Reference><Reference><Citation>M. S. Khan, S. D. Anker, T. Friede, et&#xa0;al., &#x201c;Minimal Clinically Important Differences in 6&#x2010;Minute Walk Test in Patients With HFrEF and Iron Deficiency,&#x201d; Journal of Cardiac Failure 29 (2023): 760&#x2013;770.</Citation></Reference><Reference><Citation>T. Behrendt, R. Bielitzki, M. Behrens, F. Herold, and L. Schega, &#x201c;Effects of Intermittent Hypoxia&#x2010;Hyperoxia on Performance&#x2010; and Health&#x2010;Related Outcomes in Humans: A Systematic Review,&#x201d; Sports Medicine &#x2010; Open 8 (2022): 70, https://doi.org/10.1186/s40798&#x2010;022&#x2010;00450&#x2010;x.</Citation></Reference><Reference><Citation>O. Girard, F. Brocherie, P. S. R. Goods, and G. P. Millet, &#x201c;An Updated Panorama of &#x201c;Living low&#x2010;Training High&#x201d; Altitude/Hypoxic Methods,&#x201d; Frontiers in Sports and Active Living 2 (2020): 26, https://doi.org/10.3389/fspor.2020.00026.</Citation></Reference><Reference><Citation>O. Girard, F. Brocherie, and G. P. Millet, &#x201c;Effects of Altitude/Hypoxia on Single&#x2010; and Multiple&#x2010;Sprint Performance: A Comprehensive Review,&#x201d; Sports Medicine 47 (2017): 1931&#x2013;1949, https://doi.org/10.1007/s40279&#x2010;017&#x2010;0733&#x2010;z.</Citation></Reference><Reference><Citation>Z. O. Serebrovska, E. Y. Chong, T. V. Serebrovska, L. V. Tumanovska, and L. Xi, &#x201c;Hypoxia, HIF&#x2010;1&#x3b1;, and COVID&#x2010;19: From Pathogenic Factors to Potential Therapeutic Targets,&#x201d; Acta Pharmacologica Sinica 41 (2020): 1539&#x2013;1546.</Citation></Reference><Reference><Citation>A. &#x17b;ebrowska, D. Jastrz&#x119;bski, E. Sadowska&#x2010;Kr&#x119;pa, M. Sikora, and C. Di Giulio, &#x201c;Comparison of the Effectiveness of High&#x2010;Intensity Interval Training in Hypoxia and Normoxia in Healthy Male Volunteers: A Pilot Study,&#x201d; BioMed Research International 2019 (2019): 7315714, https://doi.org/10.1155/2019/7315714.</Citation></Reference><Reference><Citation>A. Hadanny and S. Efrati, &#x201c;The Hyperoxic&#x2010;Hypoxic Paradox,&#x201d; Biomolecules 10 (2020): 958, https://doi.org/10.3390/biom10060958.</Citation></Reference><Reference><Citation>A. Weidemann and R. S. Johnson, &#x201c;Biology of HIF&#x2010;1 Alpha,&#x201d; Cell Death and Differentiation 15 (2008): 621&#x2013;627.</Citation></Reference><Reference><Citation>R. B. Bestetti, R. Furlan&#x2010;Daniel, and L. P. Pereira, &#x201c;COVID&#x2010;19 Myocarditis,&#x201d; Global Cardiology 2, no. 1 (2024), https://doi.org/10.4081/cardio.2024.21.</Citation></Reference><Reference><Citation>F. Cimino, C. Balestra, P. Germonpre, et&#xa0;al., &#x201c;Pulsed High Oxygen Induces a Hypoxic&#x2010;Like Response in Human Umbilical Endothelial Cells and in Humans,&#x201d; Journal of Applied Physiology 113 (2012): 1684&#x2013;1689.</Citation></Reference><Reference><Citation>C. Balestra and P. Germonpre, &#x201c;Hypoxia, a Multifaceted Phenomenon: The Example of the &#x201c;Normobaric Oxygen Paradox&#x201d;,&#x201d; European Journal of Applied Physiology 112 (2012): 4173&#x2013;4175.</Citation></Reference><Reference><Citation>S. Chacaroun, A. Borowik, S. A. Morrison, et&#xa0;al., &#x201c;Physiological Responses to two Hypoxic Conditioning Strategies in Healthy Subjects,&#x201d; Frontiers in Physiology 7 (2017): 675.</Citation></Reference><Reference><Citation>Y. V. Arkhipenko, T. G. Sazontova, and A. G. Zhukova, &#x201c;Adaptation to Periodic Hypoxia and Hyperoxia Improves Resistance of Membrane Structures in Heart, Liver, and Brain,&#x201d; Bulletin of Experimental Biology and Medicine 140 (2005): 278&#x2013;281.</Citation></Reference><Reference><Citation>A. Navarrete&#x2010;Opazo and G. S. Mitchell, &#x201c;Therapeutic Potential of Intermittent Hypoxia: A Matter of Dose,&#x201d; American Journal of Physiology Regulatory, Integrative and Comparative Physiology 307 (2014): R1181&#x2013;R1197.</Citation></Reference><Reference><Citation>M. S. Usman, A. Hamid, S. U. Qazi, et&#xa0;al., &#x201c;The Effect of SGLT2 Inhibitors on Health Status in Patients With Heart Failure: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Global Cardiology 2, no. 2 (2024), https://doi.org/10.4081/cardio.2024.35.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>